Breaking News, Collaborations & Alliances

Biohaven Announces Investment by Oberland Capital

Biohaven will receive up to $600 million to support ongoing clinical trials and the full development of its portfolio.

By: Rachel Klemovitch

Assistant Editor

Left: Matt Buten. Right: Andrew Rubinstein.

Biohaven Ltd., a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat a broad range of rare and common diseases, announced that it has entered an agreement with Oberland Capital Management LLC for an investment of up to $600 million in the company.   The funds will support ongoing clinical trials across Biohaven’s full development portfolio and support commercialization efforts in anticipation of a p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters